Modality
Fusion Protein
MOA
AuroraAi
Target
TIM-3
Pathway
Neuroinflam
AngelmanEpilepsyFabry
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
Jan 2022
→ Mar 2031
Phase 1Current
NCT03965077
1,738 pts·Epilepsy
2022-01→2030-02·Terminated
NCT04216326
2,364 pts·Angelman
2022-11→2031-03·Terminated
4,102 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-02-273.9y awayPh2 Data· Epilepsy
2031-03-265.0y awayPh2 Data· Angelman
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Termina…
P1/2
Termina…
Catalysts
Ph2 Data
2030-02-27 · 3.9y away
Epilepsy
Ph2 Data
2031-03-26 · 5.0y away
Angelman
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03965077 | Phase 1/2 | Epilepsy | Terminated | 1738 | Biomarker |
| NCT04216326 | Phase 1/2 | Angelman | Terminated | 2364 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |